Tag: Cancer: Prostate
Midlife PSA Predicts Aggressive Prostate Cancer in Black Men
Findings suggest potential for a targeted screening approach based on midlife PSA
Guideline-Discordant Prostate Cancer Imaging Up With Medicare
Patients in VA and Medicare group, VA-only group less likely to receive guideline-discordant imaging
PSA Testing Not Recommended for Prostate Cancer Screening
Odds of choosing screening up for men with family history, African descent, low socioeconomic status
Advanced Prostate Cancer Variant More Common Than Thought
Incidence of tx-emergent small-cell neuroendocrine prostate cancer 17 percent among those with mCRPC
Automated Bone Scan Index Prognostic for Prostate Cancer
aBSI validated as prognostic biomarker of survival in metastatic castration-resistant prostate cancer
Conservative Management Up for Low-Risk Prostate CA in Veterans
More conservative management and active surveillance utilized at VA hospitals from 2005 to 2015
Enzalutamide Improves Outcomes for Aggressive Prostate Cancer
Treatment led to 71 percent lower risk of metastasis or death compared to placebo
Prostate Cancer Treatment Side Effects Linked to Distress
Those with worse emotional distress also report worse urinary, sexual, bowel functions
ASCO: Overall Survival Up for African-American Men With mCRPC
Improved survival versus Caucasian men treated with docetaxel/prednisone, DP-containing regimen
PSA Level Three Months After Radiation Tx May Predict Outcome
Findings for men with intermediate- and high-risk prostate cancer
